表紙
市場調查報告書

雙特異性抗體醫藥品市場:2017-2030年

Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 283282
出版日期 內容資訊 英文 410 Pages
商品交期: 最快1-2個工作天內
價格
雙特異性抗體醫藥品市場:2017-2030年 Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
出版日期: 2020年01月31日內容資訊: 英文 410 Pages
簡介

本報告提供全球雙特異性抗體醫藥品的市場調查,抗體、單株抗體、雙特異性抗體概要,已上市產品和臨床實驗平台狀況,已上市產品及開發平台最後階段產品的主要技術、藥物簡介,已上市產品及開發平台最後階段產品的市場規模的變化與預測,企業間的聯盟、合作關係趨勢,產品的生命週期管理策略及促銷/行銷策略的案例研究等彙整資料。

第1章 序

第2章 摘要整理

第3章 簡介

  • 概要
  • 抗體的概念
  • 抗體結構
  • 抗體的作用機制
  • 單株抗體
  • 抗體醫藥品:有益的市場
  • 抗體基準的醫藥品的演進
  • 雙特異性抗體:形態
    • 單鏈基準的
    • 免疫球蛋白G基準
  • 雙特異性抗體:作用機制
  • 雙特異性抗體:用途

第4章 市場概要

  • 概要
  • 已上市產品和臨床實驗平台
  • 產品分佈:前臨床階段
  • 產品分佈:各開發階段
  • 產品分佈:各治療種類
  • 產品分佈:各作用機制
  • 產品分佈:各投藥途徑
  • 產品分佈:各形態
  • 產品分佈:各主要企業

第5章 技術平台

  • 本章概要
  • 技術平台清單
  • 技術簡介
    • BiclonicsR:Merus
    • Bispecific T-cell Engager (BiTER):Amgen
    • Dual-Affinity Re-Targeting (DARTR):MacroGenics
    • Modular Antibody Technology?:F-star
    • TandAbR:Affimed
    • ADAPTIR?:Aptevo Therapeutics
    • CrossMAb Technology:Roche
    • DuoBodyR:Genmab
    • NanobodyR:Ablynx
    • XmAb? Antibody Engineering Platform:Xencor

第6章 藥物簡介

  • 本章概要
  • BLINCYTOR / burinatsumomabu (Amgen)
  • emishizumabu / RG6013 (中外製藥 / Roche)
  • ABT-981 (AbbVie)
  • ozorarizumabu / ATN103 (Ablynx、Eddingpharm、大正製藥)
  • AFM13 (Affimed)
  • Istiratumab / MM-141 (Merrimack Pharmaceuticals)
  • MEDI3902 (MedImmune /AstraZeneca)
  • RG7716 / RO6867461 (Roche / Genentech)
  • SAR156597 (Sanofi)
  • Vobarilizumab, ALX-0061 (Ablynx)

第7章 市場預測、市場機會分析

  • 本章概要
  • 範圍、規定
  • 預測手法
  • 整體市場
  • 市場預測:各藥物
    • BLINCYTOR (Amgen)
    • AFM13 (Affimed)
    • Istiratumab (Merrimack Pharmaceuticals)
    • emishizumabu (中外製藥)
    • ABT-981 (AbbVie)
    • Vobarilizumab (Ablynx)
    • MEDI3902 (AbbVie)
    • RG7716 (Roche)
    • SAR156597 (Sanofi)

第8章 聯盟、合作

  • 本章概要
  • 聯盟模式
  • 聯盟清單
  • 聯盟分析
    • 各聯盟年度
    • 盟聯各類型
    • 各治療區域
    • 不過按活躍的企業:聯盟數

第9章 重要考察

  • 本章概要
  • 開發平台:開發者環境
  • 開發平台:治療區域分析
  • 雙重抗體生成平台:比較分析
  • 雷達表分析

第10章 案例研究:生命週期管理策略

  • 本章概要
  • 生命週期管理策略
  • 適應症擴大策略

第11章 案例研究:促銷/行銷策略

  • 本章概要
  • 促銷宣傳活動的各種途徑
  • 摘要:產品網站分析
  • 摘要:患者支援服務、infomatibudaunrodo
  • 摘要:會議的存在感
  • BLINCYTOR:促銷/行銷策略
  • IclusigR:促銷/行銷策略
  • MarqiboR:促銷分析

第12章 SWOT分析

第13章 總論

第14章 採訪記錄

第15章 附錄 1:圖表資料

第16章 附錄 2:企業、組織清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Example Insights:

Close to 50,000 patients were estimated to have been enrolled in clinical trials evaluating bispecific antibody therapeutics, across various geographical locations and phases of development.

Overview:

The first monoclonal antibody, Orthoclone OKT3®, was approved in 1986 by the FDA. Since then, a number of antibody therapeutics (more than 100) have been marketed for the treatment of patients suffering from various disease indications, primarily malignant tumors and other rare disorders. Despite the success, these drugs are associated with several limitations, such as increased patient resistance and a general lack of understanding of in vivo mechanisms of action. The aforementioned challenges and impending patent expiries of some of the blockbuster monoclonal antibodies have compelled the researchers and pharmaceutical companies to redesign these drugs and / or find new analogues. To further improve the specificity, efficacy and safety of monoclonal antibodies, the focus has gradually shifted towards the development of next generation recombinant antibodies, such as antibody-drug conjugates (ADCs), bispecific and multispecific antibodies, and antibody fragments and antibody-like proteins (ALPs).

Bispecific antibodies are a novel class of antibody therapeutics that act by simultaneously binding two separate and unique antigens (or different epitopes of the same antigen). The primary mechanism of action of these therapeutics involves redirection of immune effector cells for effective killing of cancer cells by antibody-dependent cell mediated cytotoxicity (ADCC) and other cytotoxic mechanisms, such as antibody dependent cellular phagocytosis (ADCP) and complement dependent cytotoxicity (CDC). Having unique biological and pharmacological properties, as well as their availability in different formats, bispecific antibodies have emerged as promising agents for therapeutic use. Advancements related to protein and antibody engineering techniques have led to the production of close to 50 new formats in the recent years.

Till date, two bispecific antibodies, namely Blincyto® (2014) and Hemlibra® (2017), have been approved for therapeutic use. It is worth mentioning that, in 2019 (till September), Blincyto® and Hemlibra® generated revenues worth USD 232 million and USD 930 million, respectively. The growing popularity and therapeutic potential of bispecific antibodies can also be correlated to an exponential increase in the number of clinical trials; the cumulative count of trials has increased from 51 studies in 2014 to over 300 studies in 2019 (till September). More than 300 bispecific drug candidates are currently in clinical / preclinical stages. In fact, multiple licensing agreements, between drug developers and technology providers, have also been inked in the past few years to advance the development of pipeline drug candidates.

Scope of the Report:

The “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment.
  • A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain.
  • Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available).
  • Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates and antibody formats) across different therapeutic areas and stages of development and [B] a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies, number of ongoing clinical trials, target disease indications, number of publications and the number of companies that are developing these molecules.
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action, target therapeutic area and partnership activity.
  • An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals.
  • A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO.
  • A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for bispecific antibody therapeutics, for the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (solid tumors, hematological malignancies, genetic disorders, autoimmune disorders, infectious diseases, inflammatory disorders, metabolic disorders, eye disorders, skin diseases and others), [B] different mechanisms of action (T-cell retargeting / activation, checkpoint immunomodulation, cytokines retargeting / neutralization, NK-cell retargeting / activation and others), [C] key targets (CD19 x CD22, CD3 x CD19, CD3 x CD20, CD30 x CD16A, Factor Ixa x Factor X, HER2 x HER2, ICOS x BAFF, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F and others), [D] type of antibody formats (asymmetric, fragments, symmetric and others), [E] key players, and [F] key geographical regions (North America, Europe, Asia Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Martin Steiner (Chief Executive Officer, Synimmune)
  • Ludger Große-Hovest (Chief Scientific Officer, Synimmune)
  • Jane Dancer (Chief Business Officer, F-Star)
  • Siobhan Pomeroy (Senior Director, Business Development, Cytom X)
  • Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the market for bispecific antibody therapeutics and its likely evolution in the mid to long term.

Chapter 3 provides a general overview of antibodies, including their historical background, structure, and the different types of antibodies available, along with their mechanisms of action. In addition, the chapter highlights the evolution of antibody-based therapeutics over the last few years. It also features a discussion on bispecific antibodies, elaborating on the different bispecific formats that are currently available, mechanisms of action of various products / product candidates and their applications.

Chapter 4 provides information on over 250 bispecific antibody drug candidates that are either approved or in different stages of development (clinical and preclinical / discovery). It features an analysis of drug developers on basis of various parameters, such as year of establishment, company size and geographical location, phase of development (marketed, clinical, and preclinical / discovery stage) of the pipeline molecules, target antigens, type of antibody format (symmetric antibody format, asymmetric antibody format, fragments and others), mechanism of action, target disease indication(s), therapeutic area, broader disease segment (oncology / non-oncology), route of administration and patient segment.

Chapter 5 includes a list of innovative technology platforms that are either currently available, or being developed by various firms, for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. Each profile contains details on the technology, including the pipeline molecules being developed using the technology, its advantages and partnerships established related to the technology. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and the size of the developer company. In addition, it features a schematic world map representation, highlighting the geographical locations of technology developers, along with the symbol representation for drug portfolio for each technology.

Chapter 6 provides detailed profiles of marketed drugs and mid to late stage (phase II and phase III) candidates. Each profile provides information on the drug overview, including route of administration, developer, highest phase of development, primary indication, therapeutic area, special designation (if any), key targets, mechanism of action, technology used, current status of development, information on clinical studies and key clinical trial results of the drug, antibody format (if available) and construct (if available). It also includes an overview of the developer, its financial details and annual sales of the drug, in case of approved drugs.

Chapter 7 is a compilation of key insights featuring a grid analysis, representing the distribution of pipeline (on the basis of mechanisms of action of product candidates and antibody formats) across different therapeutic areas and stages of development, and a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on various parameters, including the number of bispecific antibodies, number of ongoing clinical trials, target disease indications, number of publications and the number of companies that are developing these molecules. It also presents a detailed logo landscape of the companies engaged in the development of bispecific antibody-based products, distributed based on the status of development of their pipeline candidates and size of the company (small, mid-sized and large companies).

Chapter 8 highlights big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action, target therapeutic area and partnership activity.

Chapter 9 features the different partnership models and the most common forms of deals / agreements that have been inked amongst players in this market between 2016 and 2019 (till September). It also presents an analysis of the various collaboration agreements signed in this domain, based on the year of partnership, type of partnership, therapeutic area, most active developers (in terms of number of partnerships) and most active contract manufacturers (in terms of number of manufacturing agreements).

Chapter 10 highlights the key manufacturing steps involved, and challenges associated with the manufacturing of bispecific antibodies. In addition, it consists a list of CMOs and CROs involved in this domain along with the details on their headquarters, year of establishment and other specific information, such as scale of operation of CMOs and research services offered by CROs. The chapter also highlights the key points that bispecific antibody developers need to consider while or selecting a suitable CRO / CMO.

Chapter 11 presents an analysis of the various clinical trials of bispecific antibodies registered across the world (which have last update of 2019). The analysis was done for clinical trials across various parameters, such as trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial based on the number of trails and number of patients enrolled.

Chapter 12 is a review of regulatory guidelines issued by the ICH, WHO and FDA related to the development of bispecific antibodies. In addition, it provides details related to the responses of the various pharmaceutical industries to the FDA guidelines.

Chapter 13 highlights the key promotional strategies that are being implemented by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®, and comparison of both the drugs based on the information available on their respective websites. The promotional aspects covered in the chapter include the drug overview, details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings, informative downloadable content, and product visibility in scientific conferences.

Chapter 14 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall bispecific antibody therapeutic market.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of bispecific antibody therapeutics that are either marketed or in advanced stages of clinical development (phase II and phase III). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key therapeutic areas (solid tumors, hematological malignancies, genetic disorders, autoimmune disorders, infectious diseases, inflammatory disorders, metabolic disorders, eye disorders, skin diseases and others), key mechanisms of action (T-cell retargeting / activation, checkpoint immunomodulation, cytokines retargeting / neutralization, NK-cell retargeting / activation and others), [C] key targets (CD19 x CD22, CD3 x CD19, CD3 x CD20, CD30 x CD16A, Factor Ixa x Factor X, HER2 x HER2, ICOS x BAFF, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F and others), [D] type of antibody format (asymmetric, fragments, symmetric and others), [E] key players, and [F] key geographical regions (North America, Europe, Asia Pacific and Rest of the World).

Chapter 16 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the bispecific antibody therapeutics industry.

Chapter 17 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Martin Steiner (Chief Executive Officer, Synimmune), Ludge Große-Hovest (Founder and Chief Scientific Officer, Synimmune), Jane Dancer (Chief Business Officer, F-Star), Siobhan Pomeroy (Senior Director, Business Development, Cytom X) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Concept of an Antibody
  • 3.3. Structure of an Antibody
  • 3.4. Functions of an Antibody
  • 3.5. Mechanism of Action of an Antibody
  • 3.6. Concept of Monoclonal Antibodies
  • 3.7. Antibody Therapeutics
  • 3.8. Historical Evolution of Antibody Therapeutics
  • 3.9. Types of Advanced Antibody Therapeutics
    • 3.9.1. Fc Engineered and Glycoengineered Antibodies
    • 3.9.2. Antibody Fragments
    • 3.9.3. Fusion Proteins
    • 3.9.4. Intrabodies
    • 3.9.5. Bispecific Antibodies
  • 3.10. Bispecific Antibody Formats
    • 3.10.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
      • 3.10.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
      • 3.10.1.2. Bispecific Single-Domain Antibody Fusion Proteins
      • 3.10.1.3. Diabodies / Diabody Derivatives
      • 3.10.1.4. Fusion Proteins
    • 3.10.2. Immunoglobulin G (IgG)-based Formats (Fc Dependent Antibody Formats)
      • 3.10.2.1. Quadromas
      • 3.10.2.2. Knobs-Into-Holes
      • 3.10.2.3. Dual Variable Domain Ig
      • 3.10.2.4. IgG-scFv
      • 3.10.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
      • 3.10.2.6. Half Molecule Exchange
      • 3.10.2.7. kλ- Bodies
  • 3.11. Mechanisms of Action of Bispecific Antibodies
    • 3.11.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
    • 3.11.2. Directly Targeting Malignant / Tumor Cells
    • 3.11.3. Retargeting of Toxins
    • 3.11.5. Targeting Tumor Angiogenesis
    • 3.11.6. Other Mechanisms
  • 3.12. Applications of Bispecific Antibodies

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Bispecific Antibody Therapeutics: Developer Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location
  • 4.3. Bispecific Antibody Therapeutics: Clinical Pipeline
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Target Antigen
    • 4.3.3. Analysis by Type of Antibody Format
    • 4.3.4. Analysis by Mechanism of Action
    • 4.3.5. Analysis by Disease Indication
    • 4.3.6. Analysis by Therapeutic Area
    • 4.3.7. Analysis by Broader Disease Segment
    • 4.3.8. Analysis by Route of Administration
    • 4.3.9. Analysis by Mode of Administration
    • 4.3.10. Analysis by Patient Segment
  • 4.4. Bispecific Antibody Therapeutics: Early Stage Pipeline
    • 4.4.1. Analysis by Phase of Development
    • 4.4.2. Analysis by Target Antigen
    • 4.4.3. Analysis by Type of Antibody Format
    • 4.4.4. Analysis by Mechanism of Action
    • 4.4.5. Analysis by Therapeutic Area
    • 4.4.6. Analysis by Broader Disease Segment

5. BISPECIFIC ANTIBODY THERAPEUTICS: TECHNOLOGY PLATFORMS

  • 5.1. Chapter Overview
  • 5.2. Bispecific Antibody Therapeutics: List of Technology Platforms
  • 5.3. Bispecific Antibody Therapeutics: Technology Platform Profiles
    • 5.3.1. Bispecific T-cell Engager (BiTE®) (Amgen)
      • 5.3.1.1. Overview
      • 5.3.1.2. Technology Details
      • 5.3.1.3. Structure of BiTE® Bispecific Antibodies
      • 5.3.1.4. Pipeline of BiTE® Bispecific Antibodies
      • 5.3.1.5. Advantages of BiTE® Bispecific Antibodies
      • 5.3.1.6. Partnerships and Collaborations
    • 5.3.2. DuoBody® (Genmab)
      • 5.3.2.1. Overview
      • 5.3.2.2. Technology Details
      • 5.3.2.3. Structure of DuoBody® Bispecific Antibodies
      • 5.3.2.4. Pipeline of DuoBody® Bispecific Antibodies
      • 5.3.2.5. Advantages of DuoBody® Bispecific Antibodies
      • 5.3.2.6. Partnerships and Collaborations
    • 5.3.3. Xmab™ Antibody Engineering Platform (Xencor)
      • 5.3.3.1. Overview
      • 5.3.3.2. Technology Details
      • 5.3.3.3. Pipeline of Xmab™ Bispecific Antibodies
      • 5.3.3.4. Advantages of Xmab™ Bispecific Antibodies
      • 5.3.3.5. Partnerships and Collaborations
    • 5.3.4. WuXibodyTM Bispecific Engineering Platform (WuXi Biologics)
      • 5.3.4.1. Overview
      • 5.3.4.2. Pipeline of WuXibodyTM Bispecific Antibodies
      • 5.3.4.3. Advantages of WuXibodyTM Bispecific Antibodies
      • 5.3.4.4. Partnerships and Collaborations
    • 5.3.5. Anticalin® (Pieris Pharmaceuticals)
      • 5.3.5.1. Overview
      • 5.3.5.2. Structure of Anticalin® Bispecific Fusion Proteins
      • 5.3.5.3. Pipeline of Anticalin® Bispecific Fusion Proteins
      • 5.3.5.4. Advantages of Anticalin® Bispecific antibody Platform
      • 5.3.5.5. Partnerships and Collaborations
    • 5.3.6. Azymetric™ (Zymeworks)
      • 5.3.6.1. Overview
      • 5.3.6.2. Technology Details
      • 5.3.6.3. Structure of Azymetric™ Bispecific Antibodies
      • 5.3.6.4. Pipeline of Azymetric™ Bispecific Antibodies
      • 5.3.6.5. Advantages of the AzymetricTM Bispecific Antibodies
      • 5.3.6.6. Partnerships and Collaborations
  • 5.4. Bispecific Antibody Technology Platforms: Comparative Analysis
  • 5.5. Geographical Distribution of Technology Providers

6. DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. Marketed Drug Profiles
    • 6.2.1. Blincyto™ / Blinatumomab / AMG103 / MT103 (Amgen)
      • 6.2.1.1. Company Overview
        • 6.2.1.1.1. Financial Performance
      • 6.2.1.2. Drug Overview
        • 6.2.1.2.1. Mechanism of Action and Targets
        • 6.2.1.2.2. Dosage
        • 6.2.1.2.3. Current Development Status
        • 6.2.1.2.4. Development Process
        • 6.2.1.2.5. Annual Sales
    • 6.2.2. Hemlibra® / Emicizumab / RG6013 / ACE910 / RO5534262 (Chugai Pharmaceutical / Roche)
      • 6.2.2.1. Company Overview
        • 6.2.2.1.1. Financial Performance
      • 6.2.2.2. Drug Overview
        • 6.2.2.2.1. Mechanism of Action and Targets
        • 6.2.2.2.2. Dosage
        • 6.2.2.2.3. Current Development Status
        • 6.2.2.2.4. Development Process
        • 6.2.2.2.5. Annual Sales
  • 6.3. Late Stage Drug Profiles
    • 6.3.1. RG7716 / RO6867461 / Faricimab (Roche / Genentech): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.2. Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.3. ABT-165 (AbbVie): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.4. ABY-035 (Affibody): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.5. AFM13 (Affimed): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.6. AMG 570 / MEDI0700 (Amgen): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.7. KN026 (Alphamab): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.8. KN046 (Alphamab): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.9. M1095 / ALX-0761 (Merck / Ablynx / Avillion): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.10. M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.11. MCLA-128 (Merus): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.12. MEDI3902 / Gremubamab (MedImmune /AstraZeneca): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.13. MEDI7352 (AstraZeneca): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.14. MP0250 (Molecular Partners): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.15. REGN1979 (Regeneron): Overview of Drug, Current Development Status and Clinical Results
    • 6.3.16. ZW25 (Zymeworks): Overview of Drug, Current Development Status and Clinical Results

7. KEY INSIGHTS

  • 7.1. Chapter Overview
  • 7.2. Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development
  • 7.3. Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action
  • 7.4. Key Drug Developers
  • 7.5. Logo Landscape: Analysis of Developers by Company Size

8. BENCHMARK ANALYSIS: BIG PHARMA PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Top Pharmaceutical Companies
    • 8.2.1. Analysis by Target Antigen
    • 8.2.2. Analysis by Type of Antibody Format
    • 8.2.3. Analysis by Mechanism of Action
    • 8.2.4. Analysis by Therapeutic Area
  • 8.3. Other Big Pharma Players

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Therapeutic Area
    • 9.3.4. Most Active Developers: Analysis by Number of Partnerships
    • 9.3.5. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
    • 9.3.6. Regional Analysis
    • 9.3.7. Intercontinental and Intracontinental Agreements

10. CONTRACT SERIVES FOR BISPECIFIC ANTIBODY THERAPEUTICS

  • 10.1. Chapter Overview
  • 10.2. Manufacturing of Bispecific Antibody Therapeutics
    • 10.2.1. Key Manufacturing Steps and Considerations
    • 10.2.2. Challenges Associated with Manufacturing
    • 10.2.3. Contract Manufacturing Organizations (CMOs)
      • 10.2.3.1. Introduction to CMOs
      • 10.2.3.2. Bispecific Antibody Therapeutics: List of CMOs
    • 10.2.4. Contract Research Organizations (CROs)
      • 10.2.4.1. Introduction to CROs
      • 10.2.4.2. Bispecific Antibody Therapeutics: List of CROs
  • 10.3. Key Considerations for Selecting a Suitable CMO / CRO Partner

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Methodology
  • 11.3. Bispecific Antibody Therapeutics: List of Clinical Trials
  • 11.4. Bispecific Antibody Therapeutics: Clinical Trial Analysis
    • 11.4.1. Analysis by Trial Registration Year
    • 11.4.2. Analysis by Trial Recruitment Status
    • 11.4.3. Analysis by Trial Phase
    • 11.4.4. Analysis by Trial Design
    • 11.4.5. Analysis by Disease Indication
    • 11.4.6. Analysis by Therapeutic Area
    • 11.4.7. Most Active Developers
    • 11.4.8. Analysis by Number of Clinical Trials and Geography
    • 11.4.9. Analysis by Enrolled Patient Population and Geography

12. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES

  • 12.1. Chapter Overview
  • 12.2. Guidelines Issued by Regulatory Authorities
    • 12.2.1. US Food and Drug Administration (FDA)
    • 12.2.2. World Health Organization (WHO)
    • 12.2.3. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use

13. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES

  • 13.1. Chapter Overview
  • 13.2. Overview of Channels Used for Promotional Campaigns
  • 13.3. Summary: Product Website Analysis
  • 13.4. Summary: Patient Support Services and Informative Downloads
  • 13.5. Promotional Analysis: Blincyto™
    • 13.5.1. Drug Overview
    • 13.5.2. Product Website analysis
      • 13.5.2.1. Messages for Healthcare Professionals
        • 13.5.2.1.1. For MRD Positive B cell precursor ALL
        • 13.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
      • 13.5.2.2. Message for Patients
    • 13.5.3. Patient Support Services and Informative Downloads
    • 13.5.4. Other Promotional Strategies
      • 13.5.4.1. Presence in Conferences
  • 13.6. Promotional Analysis: Hemlibra®
    • 13.6.1. Drug Overview
    • 13.6.2. Product Website Analysis
      • 13.6.2.1. Messages for Healthcare Professionals
        • 13.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
        • 13.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
      • 13.6.2.3. Messages for Patients
    • 13.6.3. Patient Support Services and Informative Downloads
      • 13.6.3.1. Co-pay Program
      • 13.6.3.2. Independent Co-pay Assistance Foundation
      • 13.6.3.3. Genentech Patient Foundation
    • 13.6.4. Other Promotional Strategies
      • 13.6.4.1. Presence in Conferences

14. SWOT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Strengths
  • 14.3. Weaknesses
  • 14.4. Opportunities
  • 14.5. Threats
  • 14.6. Concluding Remarks

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Scope and Limitations
  • 15.3. Forecast Methodology and Key Assumptions
  • 15.4. Overall Bispecific Antibody Therapeutics Market, 2019-2030
    • 15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Key Therapeutic Areas
    • 15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanisms of Action
    • 15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Key Targets
    • 15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Formats
    • 15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players
    • 15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Key Geographical Regions
  • 15.5. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts
    • 15.5.1. Blincyto™
      • 15.5.1.1 Target Patient Population
      • 15.5.1.2 Sales Forecast
      • 15.5.1.3. Net Present Value
      • 15.5.1.4. Value Creation Analysis
    • 15.5.2. Hemlibra®
      • 15.5.2.1 Target Patient Population
      • 15.5.2.2 Sales Forecast
      • 15.5.2.3. Net Present Value
      • 15.5.2.4. Value Creation Analysis
    • 15.5.3. RG7716
      • 15.5.3.1 Target Patient Population
      • 15.5.3.2 Sales Forecast
      • 15.5.3.3. Net Present Value
      • 15.5.3.4. Value Creation Analysis
    • 15.5.4. Ozoralizumab
      • 15.5.4.1 Target Patient Population
      • 15.5.4.2 Sales Forecast
      • 15.5.4.3. Net Present Value
      • 15.5.4.4. Value Creation Analysis
    • 15.5.5. ABT-165
      • 15.5.5.1 Target Patient Population
      • 15.5.5.2 Sales Forecast
      • 15.5.5.3. Net Present Value
      • 15.5.5.4. Value Creation Analysis
    • 15.5.6. ABY-035
      • 15.5.6.1 Target Patient Population
      • 15.5.6.2 Sales Forecast
      • 15.5.6.3. Net Present Value
      • 15.5.6.4. Value Creation Analysis
    • 15.5.7. AFM13
      • 15.5.7.1 Target Patient Population
      • 15.5.7.2 Sales Forecast
      • 15.5.7.3. Net Present Value
      • 15.5.7.4. Value Creation Analysis
    • 15.5.8. AMG 570
      • 15.5.8.1 Target Patient Population
      • 15.5.8.2 Sales Forecast
      • 15.5.8.3. Net Present Value
      • 15.5.8.4. Value Creation Analysis
    • 15.5.9. KN026
      • 15.5.9.1 Target Patient Population
      • 15.5.9.2 Sales Forecast
      • 15.5.9.3. Net Present Value
      • 15.5.9.4. Value Creation Analysis
    • 15.5.10. KN046
      • 15.5.10.1 Target Patient Population
      • 15.5.10.2 Sales Forecast
      • 15.5.10.3. Net Present Value
      • 15.5.10.4. Value Creation Analysis
    • 15.5.11. M1095
      • 15.5.11.1 Target Patient Population
      • 15.5.11.2 Sales Forecast
      • 15.5.11.3. Net Present Value
      • 15.5.11.4. Value Creation Analysis
    • 15.5.12. M7824
      • 15.5.12.1 Target Patient Population
      • 15.5.12.2 Sales Forecast
      • 15.5.12.3. Net Present Value
      • 15.5.12.4. Value Creation Analysis
    • 15.5.13. MCLA-128
      • 15.5.13.1 Target Patient Population
      • 15.5.13.2 Sales Forecast
      • 15.5.13.3. Net Present Value
      • 15.5.13.4. Value Creation Analysis
    • 15.5.14. MEDI3902
      • 15.5.14.1 Target Patient Population
      • 15.5.14.2 Sales Forecast
      • 15.5.14.3. Net Present Value
      • 15.5.14.4. Value Creation Analysis
    • 15.5.15. MEDI7352
      • 15.5.15.1 Target Patient Population
      • 15.5.15.2 Sales Forecast
      • 15.5.15.3. Net Present Value
      • 15.5.15.4. Value Creation Analysis
    • 15.5.16. MP0250
      • 15.5.16.1 Target Patient Population
      • 15.5.16.2 Sales Forecast
      • 15.5.16.3. Net Present Value
      • 15.5.16.4. Value Creation Analysis
    • 15.5.17. REGN1979
      • 15.5.17.1 Target Patient Population
      • 15.5.17.2 Sales Forecast
      • 15.5.17.3. Net Present Value
      • 15.5.17.4. Value Creation Analysis
  • 15.18. ZW25
    • 15.5.18.1 Target Patient Population
    • 15.5.18.2 Sales Forecast
    • 15.5.18.3. Net Present Value
    • 15.5.18.4. Value Creation Analysis

16. CONCLUDING REMARKS

17. EXECUTIVE INSIGHTS

  • 17.1. Chapter Overview
  • 17.2. Cytom X
    • 17.2.1. Company Snapshot
    • 17.2.2. Interview Transcript: Siobhan Pomeroy, Senior Director, Business Development
  • 17.3. F-star
    • 17.3.1. Company Snapshot
    • 17.3.2. Interview Transcript: Jane Dancer, Chief Business Officer
  • 17.4. Innovent Biologics
    • 17.4.1. Company Snapshot
    • 17.4.2. Interview Transcript: Yinjue Wang, Associate Director, Process Development
  • 17.5. Synimmune
    • 17.4.1. Company Snapshot
    • 17.4.2. Interview Transcript: Ludger Große-Hovest, Chief Scientific Officer, and Martin Steiner, Chief Executive Officer

18 APPENDIX 1: TABULATED DATA

19 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

  • Figure 3.1. History of Evolution of Antibodies
  • Figure 3.2. Basic Structure of an Antibody
  • Figure 3.3. Mechanisms of Action of Antibody-based Therapeutics
  • Figure 3.4. Revenues of the Top 15 Therapeutic Antibodies, 2018 (USD Billion)
  • Figure 3.5. Symmetric and Asymmetric Bispecific Antibodies
  • Figure 4.1. Bispecific Antibody Developers: Distribution by Year of Establishment
  • Figure 4.2. Bispecific Antibody Developers: Distribution by Company Size
  • Figure 4.3. Bispecific Antibody Developers: Distribution by Geographical Location
  • Figure 4.4. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Phase of Development
  • Figure 4.5. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Target Antigen
  • Figure 4.6. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Type of Antibody Format
  • Figure 4.7. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mechanism of Action
  • Figure 4.8. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Disease Indication
  • Figure 4.9. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Therapeutic Area
  • Figure 4.10. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Broader Disease Segment
  • Figure 4.11. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Route of Administration
  • Figure 4.12. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mode of Administration
  • Figure 4.13. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Patient Segment
  • Figure 4.14. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Dosing Frequency
  • Figure 4.15. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Phase of Development
  • Figure 4.16. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Target Antigen
  • Figure 4.17. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Mechanism of Action
  • Figure 4.18. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Therapeutic Area
  • Figure 4.19. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Broader Disease Indication
  • Figure 5.1. Structure of BiTE® Bispecific Antibody
  • Figure 5.2. Structure of DuoBody® Bispecific Antibody
  • Figure 5.3. Structure of Anticalin® Bispecific Fusion Proteins
  • Figure 5.4. Structure of Azymetric™ Bispecific Fusion Proteins
  • Figure 5.5. Bispecific Antibody Technology Platforms: 3-Dimensional Comparative Bubble Analysis
  • Figure 5.6. Bispecific Antibody Technology Providers: Geographical Distribution
  • Figure 6.1. Amgen: Annual Revenues, 2014-H1 2019 (USD Billion)
  • Figure 6.2. Blincyto®: Annual Sales, 2015-H1 2019 (USD Million)
  • Figure 6.3. Chugai Pharmaceutical: Annual Revenues, 2014-H1 2019 (JPY Billion)
  • Figure 7.1. Bispecific Antibody Therapeutics: Distribution by Therapeutic Area and Phase of Development
  • Figure 7.2. Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action
  • Figure 7.3. Bispecific Antibody Therapeutics: Key Developers
  • Figure 7.4. Logo Landscape: Distribution of Developers by Company Size
  • Figure 8.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 8.2. Big Pharma Players: Distribution by Type of Target Antigen
  • Figure 8.3. Big Pharma Players: Distribution by Type of Antibody Format
  • Figure 8.4. Big Pharma Players: Distribution by Mechanism of Action
  • Figure 8.5. Big Pharma Players: Distribution by Therapeutic Area
  • Figure 8.5. Big Pharma Players: Heat Map Analysis of Other Big Players
  • Figure 9.1. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2019
  • Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 9.4. Partnerships and Collaborations: Most Active Developers
  • Figure 9.5. Partnerships and Collaborations: Most Active Contract Manufacturers
  • Figure 9.6. Partnerships and Collaborations: Regional Distribution
  • Figure 9.7. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 11.1. Clinical Trial Analysis: Distribution by Trial Registration Year, 2014-2019
  • Figure 11.2. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Recruitment Status
  • Figure 11.3. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Phase of Development
  • Figure 11.4. Clinical Trial Analysis: Distribution by Trial Design
  • Figure 11.5. Clinical Trial Analysis: Distribution by Disease Indication
  • Figure 11.6. Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 11.7. Clinical Trial Analysis: Most Active Industry Players
  • Figure 11.8. Clinical Trial Analysis: Most Active Non-Industry Players
  • Figure 11.9. Clinical Trial Analysis: Geographical Distribution of Number of Clinical Trials
  • Figure 11.10. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
  • Figure 12.1. FDA Considerations for Development of Bispecific Antibodies
  • Figure 13.1. Channels Used for Promotional Campaigns
  • Figure 13.2. Summary: Product Website Analysis
  • Figure 13.3. Summary: Patient Support Services and Informative Downloads
  • Figure 13.4. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, BLAST Study Results)
  • Figure 13.5. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, TOWER Study Results)
  • Figure 13.6. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, Ph (+) Relapsed / Refractory B-cell Precursor ALL)
  • Figure 13.7. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, Relapsed / Refractory B-cell Precursor ALL (Pediatrics))
  • Figure 13.8. Blincyto®: Product Website Analysis (Messages for Patients)
  • Figure 13.9. Blincyto®: Amgen Assist 360 Nurse Ambassador
  • Figure 13.10. Blincyto®: Presence in Conferences
  • Figure 13.11. Hemlibra®: Product Website Analysis (Messages for Healthcare Professionals, Hemophilia A without Factor VIII Inhibitors)
  • Figure 13.12. Hemlibra®: Product Website Analysis (Messages for Healthcare Professionals, Hemophilia A with Factor VIII Inhibitors)
  • Figure 13.13. Hemlibra®: Product Website Analysis (Messages for Patients)
  • Figure 13.14. Hemlibra®: Presence in Conferences
  • Figure 14.1. Bispecific Antibody Therapeutics: SWOT Analysis
  • Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 15.1. Overall Bispecific Antibody Therapeutics Market, 2019-2030: Base Scenario (USD Million)
  • Figure 15.2. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2019, 2025 and 2030 (USD Million)
  • Figure 15.3. Bispecific Antibody Therapeutics Market: Distribution by Type of Antibody Format, 2019, 2025 and 2030 (USD Million)
  • Figure 15.4. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2019, 2025 and 2030 (USD Million)
  • Figure 15.5. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2019, 2025 and 2030 (USD Million)
  • Figure 15.6. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2019, 2025 and 2030 (USD Million)
  • Figure 15.7. Bispecific Antibody Therapeutics Market: Distribution by Geographical Regions, 2019, 2025 and 2030 (USD Million)
  • Figure 15.8. Blincyto® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.9. Hemlibra® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.10. RG7716 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.11 Ozoralizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.12. ABT-165 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.13. ABY-035 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.14. AFM13 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.15. AMG 570 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.16. KN026 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.17. KN046 Sale Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.18. M1095 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.19. M7824 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.20. MCLA-128 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.21. MEDI3902 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.22 MEDI7352 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.23. MP0250 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.24. REGN1979 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 15.25. ZW25 Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

  • Table 3.1. Isotypes of Mammalian Antibodies
  • Table 3.2. Mechanisms of Action of Therapeutic Antibodies
  • Table 3.3. Top Therapeutic Antibodies, 2018
  • Table 4.1. Bispecific Antibody Therapeutics: Information on Clinical Pipeline
  • Table 4.2. Bispecific Antibody Therapeutics: Additional Information on Clinical Pipeline
  • Table 4.3. Bispecific Antibody Therapeutics: Information on Early Stage Pipeline
  • Table 4.4. Bispecific Antibody Therapeutics: Information on Early Stage Pipeline
  • Table 5.1. Bispecific Antibody Therapeutics: List of Technology Platforms
  • Table 5.2. BiTE® Bispecific Antibodies: Development Pipeline
  • Table 5.3. BiTE® Bispecific Antibodies: Partnerships and Collaborations
  • Table 5.4. DuoBody® Bispecific Antibodies: Development Pipeline
  • Table 5.5. DuoBody® Bispecific Antibodies: Partnerships and Collaborations
  • Table 5.6. XmAb™ Bispecific Antibodies: Development Pipeline
  • Table 5.7. Xmab™ Bispecific Antibodies: Partnerships and Collaborations
  • Table 5.8. WuXibodyTM Bispecific Antibodies: Development Pipeline
  • Table 5.9. WuXibodyTM Bispecific Antibodies: Partnerships and Collaborations
  • Table 5.10. Anticalin® Bispecific Fusion Proteins: Development Pipeline
  • Table 5.11. Anticalin® Bispecific Fusion Proteins: Partnerships and Collaborations
  • Table 5.12. Azymetric™ Bispecific Antibodies: Development Pipeline
  • Table 5.13. Azymetric™ Bispecific Antibodies: Partnerships and Collaborations
  • Table 6.1. Amgen: Bispecific Antibody Product Portfolio
  • Table 6.2. Chugai Pharmaceutical: Bispecific Antibody Product Portfolio
  • Table 6.3. Drug Profile: RG7716
  • Table 6.4. Drug Profile: Ozoralizumab
  • Table 6.5. Drug Profile: ABT-165
  • Table 6.6. Drug Profile: ABY-035
  • Table 6.7. Drug Profile: AFM13
  • Table 6.8. Drug Profile: AMG 570
  • Table 6.9. Drug Profile: KN026
  • Table 6.10. Drug Profile: KN046
  • Table 6.11. Drug Profile: M1095
  • Table 6.12. Drug Profile: M7824
  • Table 6.13. Drug Profile: MCLA-128
  • Table 6.14. Drug Profile: MEDI3902
  • Table 6.15. Drug Profile: MEDI7352
  • Table 6.16. Drug Profile: MP0250
  • Table 6.17. Drug Profile: REGN1979
  • Table 6.18. Drug Profile: ZW25
  • Table 7.1. Bispecific Antibody Therapeutics: Spider-Web Analysis (Input Data)
  • Table 9.1. Bispecific Antibody Therapeutics: Partnerships and Collaborations, 2016-2019
  • Table 10.1. List of Bispecific Antibody CMOs: Information on Company Specifications and Type of Manufacturer
  • Table 10.2. List of Bispecific Antibody CMOs: Information on Scale of Operation, Facility Location and Production Capacity
  • Table 10.3. List of Bispecific antibody CROs: Information on Company Specifications and Type of Service
  • Table 13.1. Blincyto®: Drug Overview
  • Table 13.2. Hemlibra®: Drug Overview
  • Table 14.1. Bispecific Antibody Therapeutics: List of CMOs
  • Table 15.1. Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
  • Table 15.2. Blincyto®: Target Patient Population
  • Table 15.3. Blincyto®: Net Present Value (USD Million)
  • Table 15.4. Blincyto®: Value Creation Analysis (USD Million)
  • Table 15.5. Hemlibra®: Target Patient Population
  • Table 15.6. Hemlibra®: Net Present Value (USD Million)
  • Table 15.7. Hemlibra®: Value Creation Analysis (USD Million)
  • Table 15.8. RG7716: Target Patient Population
  • Table 15.9. RG7716: Net Present Value (USD Million)
  • Table 15.10. RG7716: Value Creation Analysis (USD Million)
  • Table 15.11. Ozoralizumab: Target Patient Population
  • Table 15:12. Ozoralizumab: Net Present Value (USD Million)
  • Table 15.13. Ozoralizumab: Value Creation Analysis (USD Million)
  • Table 15.14. ABT-165: Target Patient Population
  • Table 15.15. ABT-165: Net Present Value (USD Million)
  • Table 15.16. ABT-165: Value Creation Analysis (USD Million)
  • Table 15.17. ABY-035: Target Patient Population
  • Table 15.18. ABY-035: Net Present Value (USD Million)
  • Table 15.19. ABY-035: Value Creation Analysis (USD Million)
  • Table 15.20. AFM13: Target Patient Population
  • Table 15.21. AFM13: Net Present Value (USD Million)
  • Table 15.22. AFM13: Value Creation Analysis (USD Million)
  • Table 15.23. AMG 570: Target Patient Population
  • Table 15.24. AMG 570: Net Present Value (USD Million)
  • Table 15.25. AMG 570: Value Creation Analysis (USD Million)
  • Table 15.26. KN026: Target Patient Population
  • Table 15.27. KN026: Net Present Value (USD Million)
  • Table 15.28. KN026: Value Creation Analysis (USD Million)
  • Table 15.29. KN046: Target Patient Population
  • Table 15.30. KN046: Net Present Value (USD Million)
  • Table 15.31. KN046: Value Creation Analysis (USD Million)
  • Table 15.32. M1095: Target Patient Population
  • Table 15.33. M1095: Net Present Value (USD Million)
  • Table 15.34. M1095: Value Creation Analysis (USD Million)
  • Table 15.35. M7824: Target Patient Population
  • Table 15.36. M7824: Net Present Value (USD Million)
  • Table 15.37. M7824: Value Creation Analysis (USD Million)
  • Table 15.38. MCLA-128: Target Patient Population
  • Table 15.39. MCLA-128: Net Present Value (USD Million)
  • Table 15.40. MCLA-128: Value Creation Analysis (USD Million)
  • Table 15.41. MEDI3902: Target Patient Population
  • Table 15.42. MEDI3902: Net Present Value (USD Million)
  • Table 15.43. MEDI3902: Value Creation Analysis (USD Million)
  • Table 15.44. MEDI7352: Target Patient Population
  • Table 15.45. MEDI7352: Net Present Value (USD Million)
  • Table 15.46. MEDI7352: Value Creation Analysis (USD Million)
  • Table 15.47. MP0250: Target Patient Population
  • Table 15.48. MP0250: Net Present Value (USD Million)
  • Table 15.49. MP0250: Value Creation Analysis (USD Million)
  • Table 15.50. REGN1979: Target Patient Population
  • Table 15.51. REGN1979: Net Present Value (USD Million)
  • Table 15.52. REGN1979: Value Creation Analysis (USD Million)
  • Table 15.53. ZW25: Target Patient Population
  • Table 15.54. ZW25: Net Present Value (USD Million)
  • Table 15.55. ZW25: Value Creation Analysis (USD Million)
  • Table 18.1. Revenues of the Top 15 Therapeutic Antibodies, 2018 (USD Billion)
  • Table 18.2. Bispecific Antibody Developers: Distribution by Year of Establishment
  • Table 18.3. Bispecific Antibody Developers: Distribution by Company Size
  • Table 18.4. Bispecific Antibody Developers: Distribution by Geographical Location
  • Table 18.5. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Phase of Development
  • Table 18.6. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Target Antigen
  • Table 18.7. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Type of Antibody Format
  • Table 18.8. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mechanism of Action
  • Table 18.9. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Disease Indication
  • Table 18.10. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Therapeutic Area
  • Table 18.11. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Broader Disease Segment
  • Table 18.12. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Route of Administration
  • Table 18.13. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mode of Administration
  • Table 18.14. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Patient Segment
  • Table 18.15. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Dosing Frequency
  • Table 18.16. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Phase of Development
  • Table 18.17. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Target Antigen
  • Table 18.18. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Mechanism of Action
  • Table 18.19. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Therapeutic Area
  • Table 18.20. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Broader Disease Indication
  • Table 18.21. Amgen: Annual Revenues, 2014-H1 2019 (USD Billion)
  • Table 18.22. Blincyto®: Annual Sales, 2015-H1 2019 (USD Million)
  • Table 18.23. Chugai Pharmaceutical: Annual Revenues, 2014-H1 2019 (JPY Billion)
  • Table 18.24. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2019
  • Table 18.25. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 18.26. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 18.27. Partnerships and Collaborations: Most Active Developers
  • Table 18.28. Partnerships and Collaborations: Most Active Contract Manufacturers
  • Table 18.29. Partnerships and Collaborations: Regional Distribution
  • Table 18.30. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 18.31. Clinical Trial Analysis: Distribution by Trial Registration Year, 2014-2019
  • Table 18.32. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Recruitment Status
  • Table 18.33. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Phase of Development
  • Table 18.34. Clinical Trial Analysis: Distribution by Trial Design
  • Table 18.35. Clinical Trial Analysis: Distribution by Disease Indication
  • Table 18.36. Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 18.37. Clinical Trial Analysis: Most Active Industry Players
  • Table 18.38. Clinical Trial Analysis: Most Active Non-Industry Players
  • Table 18.39. Clinical Trial Analysis: Geographical Distribution of Number of Clinical Trials
  • Table 18.40. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
  • Table 18.41. Blincyto®: Presence in Conferences
  • Table 18.42. Hemlibra®: Presence in Conferences
  • Table 18.43. Overall Bispecific Antibody Therapeutics Market, 2019-2030: Base Scenario (USD Million)
  • Table 18.44. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2019, 2025 and 2030 (USD Million)
  • Table 18.45. Bispecific Antibody Therapeutics Market: Distribution by Type of Antibody Format, 2019, 2025 and 2030 (USD Million)
  • Table 18.46. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2019, 2025 and 2030 (USD Million)
  • Table 18.47. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2019, 2025 and 2030 (USD Million)
  • Table 18.48. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2019, 2025 and 2030 (USD Million)
  • Table 18.49. Bispecific Antibody Therapeutics Market: Distribution by Geographical Regions, 2019, 2025 and 2030 (USD Million)
  • Table 18.50. Blincyto® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.51. Hemlibra® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.52. RG7716 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.53. Ozoralizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.54. ABT-165 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.55. ABY-035 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.56. AFM13 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.57. AMG 570 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.58. KN026 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.59. KN046 Sale Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.60. M1095 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.61. M7824 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.62. MCLA-128 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.63. MEDI3902 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.64. MEDI7352 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.65. MP0250 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.66. REGN1979 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Table 18.67. ZW25 Sales Forecast (Till 2030): Base Scenario (USD Million)

Listed Companies

  • 1. 3P Biopharmaceuticals
  • 2. Ab Studio
  • 3. AbbVie
  • 4. AbCellera
  • 5. AbClon
  • 6. ABL Bio
  • 7. Ablynx
  • 8. Abpro
  • 9. Abveris
  • 10. Abzena
  • 11. Abzyme Therapeutics
  • 12. Adicet Bio
  • 13. Adimab
  • 14. Advaxis
  • 15. Affibody
  • 16. Affimed
  • 17. AGC Biologics
  • 18. Agensys
  • 19. Agenus
  • 20. AgonOx
  • 21. Akeso Biopharma
  • 22. Alcami
  • 23. Aldevron
  • 24. Alexion Pharmaceuticals
  • 25. Alissa Pharma
  • 26. Allergan
  • 27. Alligator Bioscience
  • 28. Alphamab Oncology
  • 29. Altor BioScience
  • 30. Ambrx
  • 31. Amgen
  • 32. Amunix
  • 33. AnaptysBio
  • 34. Anogen
  • 35. Antibody Solutions
  • 36. AP Biosciences
  • 37. Aptevo Therapeutics
  • 38. ARBELE
  • 39. Array BioPharma (Now acquired by Pfizer)
  • 40. Astellas Pharma
  • 41. AstraZeneca
  • 42. Atreca
  • 43. AURA Biotechnologies
  • 44. Avacta
  • 45. AvantGen
  • 46. Avidity Biosciences
  • 47. Avillion
  • 48. Axcellerate Pharma
  • 49. Baliopharm
  • 50. Barbara Ann Karmanos Cancer Institute
  • 51. Bayer
  • 52. BeiGene
  • 53. Benhealth Biopharmaceutical
  • 54. Betta Pharmaceuticals
  • 55. BioFactura
  • 56. BioInvent
  • 57. BIOMUNEX Pharmaceuticals
  • 58. BioNTech
  • 59. Bio-Synthesis
  • 60. Biotecnol
  • 61. Biotest
  • 62. Biotheus
  • 63. BiVictriX Therapeutics
  • 64. bluebird bio
  • 65. Boehringer Ingelheim
  • 66. Brigham and Women's Hospital (BWH)
  • 67. Bristol-Myers Squibb
  • 68. Calico
  • 69. Cancer Research UK
  • 70. Catalent Biologics
  • 71. Celgene
  • 72. CELLSCRIPT
  • 73. Celonic
  • 74. Centre Leon Berard
  • 75. ChemPartner
  • 76. Chiome Bioscience
  • 77. Christian Doppler (CD) Laboratory
  • 78. Chugai Pharmaceutical
  • 79. CinnaGen
  • 80. CMC Biologics
  • 81. Cobra Biologics
  • 82. Compass Therapeutics
  • 83. Complix
  • 84. Covagen
  • 85. Creative Biolabs
  • 86. Creative Biostructure
  • 87. Crescendo Biologics
  • 88. CStone Pharmaceuticals
  • 89. CytomX Therapeutics
  • 90. Cytovance® Biologics
  • 91. Daiichi Sankyo
  • 92. Dana-Farber Cancer Institute
  • 93. DCPrime
  • 94. Denali Therapeutics
  • 95. Dong-A ST
  • 96. Dragonfly Therapeutics
  • 97. Dualogics
  • 98. Eddingpharm
  • 99. Eli Lilly
  • 100. EMD Serono
  • 101. Emergent BioSolutions
  • 102. EnGeneIC
  • 103. EngMab
  • 104. EpimAb Biotherapeutics
  • 105. Exelixis
  • 106. F-star
  • 107. Fuda Cancer Hospital
  • 108. FUJIFILM Diosynth Biotechnologies
  • 109. Fusion Antibodies
  • 110. FZata
  • 111. GEMoaB
  • 112. Genedata
  • 113. Genentech
  • 114. GENERON
  • 115. Genmab
  • 116. Gilead Sciences
  • 117. GlaxoSmithKline
  • 118. Glenmark Pharmaceuticals
  • 119. Glycotope
  • 120. GO Therapeutics
  • 121. Goodwin Biotechnology
  • 122. Greffex
  • 123. Gritstone Oncology
  • 124. GT Biopharma
  • 125. GTP Technology
  • 126. Gustave Roussy
  • 127. Hanmi Pharmaceutical
  • 128. Harbour BioMed
  • 129. Harpoon Therapeutics
  • 130. HEC Paris
  • 131. Henlix Biotech
  • 132. ICON
  • 133. IGM Biosciences
  • 134. I-Mab Biopharma
  • 135. Immatics
  • 136. Immune Biosolutions
  • 137. Immune Design
  • 138. Immune Pharmaceuticals
  • 139. Immunex
  • 140. ImmuNext
  • 141. Immunocore
  • 142. Immunomedics
  • 143. Incyte
  • 144. Inhibrx
  • 145. Innate Pharma
  • 146. Innovent Biologics
  • 147. Inovio Pharmaceuticals
  • 148. Institute for Research in Biomedicine (IRB) Barcelona
  • 149. Invenra
  • 150. IONTAS
  • 151. IQVIA
  • 152. Janssen
  • 153. Johnson & Johnson
  • 154. Just mention University of California San Diego
  • 155. JW Pharmaceutical
  • 156. Kaken Pharmaceutical
  • 157. KBI Biopharma
  • 158. Kymab
  • 159. Lava Therapeutics
  • 160. Lazarex Cancer Foundation
  • 161. LeadArtis
  • 162. LEO Pharma
  • 163. LG Chem Life Sciences
  • 164. LifeArc
  • 165. Ligand Pharmaceuticals
  • 166. Light Chain Bioscience
  • 167. Lonza
  • 168. Luye Pharma Group
  • 169. M2Gen
  • 170. MAB Discovery
  • 171. MabPlex
  • 172. MabVax Therapeutics
  • 173. MacroGenics
  • 174. Massachusetts General Hospital (MGH)
  • 175. MediaPharma
  • 176. MedImmune
  • 177. Memorial Sloan Kettering Cancer Center
  • 178. Merck
  • 179. Mereo BioPharma
  • 180. Meridian Life Science
  • 181. Merrimack Pharmaceuticals
  • 182. Merus
  • 183. Millegen
  • 184. MilliporeSigma
  • 185. Molecular Partners
  • 186. MorphoSys
  • 187. Morphotek
  • 188. NanoString
  • 189. Nantes University Hospital
  • 190. National Cancer Institute (NCI)
  • 191. National Institutes of Health
  • 192. Navarrabiomed
  • 193. Neovii Biotech
  • 194. NextCure
  • 195. NJCTTQ
  • 196. Northwestern University
  • 197. Novartis
  • 198. Novasep
  • 199. Novimmune
  • 200. Numab
  • 201. OncoMed Pharmaceuticals
  • 202. Ono Pharmaceutical
  • 203. OriMAbs
  • 204. OSE Immunotherapeutics
  • 205. Ossianix
  • 206. Pfizer
  • 207. PharmAbcine
  • 208. Pieris Pharmaceuticals
  • 209. Pierre Fabre
  • 210. Premas Biotech
  • 211. ProMab Biotechnologies
  • 212. Provention Bio
  • 213. Pure Biologics
  • 214. Pure MHC
  • 215. PX'Therapeutics
  • 216. QIMR Berghofer Medical Research Institute
  • 217. Regeneron Pharmaceuticals
  • 218. Rentschler Biotechnologie
  • 219. Rice University
  • 220. Roche
  • 221. Roger Williams Medical Center
  • 222. Sanofi
  • 223. SATT Sud-Est
  • 224. Sea Lane Biotechnologies
  • 225. Seattle Genetics
  • 226. Selexis
  • 227. SemaThera
  • 228. SENJU Pharmaceutical
  • 229. Servier
  • 230. Simcere
  • 231. Sound Biologics
  • 232. Stanford University
  • 233. Sutro Biopharma
  • 234. Swedish Orphan Biovitrum (Sobi™)
  • 235. Syapse
  • 236. Synimmune
  • 237. SystImmune
  • 238. Taisho Pharmaceutical
  • 239. Takara Bio
  • 240. Takeda Pharmaceutical
  • 241. Tango Therapeutics
  • 242. Tasly Biopharma
  • 243. Tempus
  • 244. TeneoBio
  • 245. TESARO
  • 246. TG Therapeutics
  • 247. The Hebrew University of Jerusalem
  • 248. The Institute for Protein Design (IPD)
  • 249. The Johns Hopkins University School of Medicine
  • 250. The University of Texas MD Anderson Cancer Center
  • 251. The Wistar Institute
  • 252. Theradex Oncology
  • 253. Tilos Therapeutics
  • 254. TOT BIOPHARM
  • 255. TRACON Pharmaceuticals
  • 256. Trianni
  • 257. TRIGR Therapeutics
  • 258. Tufts University School of Medicine
  • 259. UCLA AIDS Institute
  • 260. University of California
  • 261. University of Chicago
  • 262. University of Kentucky Markey Cancer Center
  • 263. University of Michigan
  • 264. University of Minnesota
  • 265. University of North Carolina
  • 266. University of Virginia
  • 267. University of Zurich
  • 268. Vall d'Hebron Institute of Oncology
  • 269. Weizmann Institute of Science
  • 270. Wisconsin Alumni Research Foundation
  • 271. WuXi AppTec
  • 272. WuXi Biologics
  • 273. Xencor
  • 274. XOMA
  • 275. Y-Biologics
  • 276. Y-mAbs Therapeutics
  • 277. Yuhan
  • 278. YUMAB
  • 279. YZY Biopharma
  • 280. Zai Lab
  • 281. Zebra Biologics
  • 282. Zhejiang Teruisi Biopharmaceutical
  • 283. Zymeworks
  • 284. Zyngenia